---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-065311"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2023-03-09T23:59:59+00:00"
generated_at: "2026-06-18T06:54:26.728423+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Akebia reports 2022 Auryxia revenue $177.1M (+24.5% YoY); net loss narrows to $92.6M

## Summary
- Q4 2022 net product revenue $49.7M (+18.1% YoY); full-year $177.1M, driven by pricing and payer mix.
- Full-year net loss $92.6M, down from $282.8M in 2021; cash $90.5M at year-end.
- Positive CHMP opinion for vadadustat (Vafseo) in Europe; potential EC approval by May 2023.
- 2023 Auryxia net product revenue guidance set at $175-180M, reflecting cautious market outlook.
- Regained vadadustat rights globally; submitted FDA Formal Dispute Resolution Request in 2022.

## SEC filing metadata
- accession: 0001193125-23-065311
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2023-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000119312523065311/0001193125-23-065311-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000119312523065311/d367644d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-065311
- JSON: https://secwatch.observer/filing/0001193125-23-065311.json
- Plain text: https://secwatch.observer/filing/0001193125-23-065311.txt

## Key facts
- Earnings Releases
  Akebia Therapeutics, Inc. reported the fiscal year ended December 31, 2022 results: revenue $292.6 million.
  - Period: the fiscal year ended December 31, 2022
  - Revenue: $292.6 million
  - Result: reported results
  source text: Total revenue was $55.2 million in the fourth quarter of 2022 compared to $59.6 million for the fourth quarter of 2021, and $292.6 million for the full-year 2022 compared to $213.6 million for full-year 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000119312523065311/0001193125-23-065311-index.htm
- Earnings Releases
  Akebia Therapeutics, Inc. reported the fourth quarter ended December 31, 2022 results: revenue $55.2 million.
  - Period: the fourth quarter ended December 31, 2022
  - Revenue: $55.2 million
  - Result: reported results
  source text: Total revenue was $55.2 million in the fourth quarter of 2022 compared to $59.6 million for the fourth quarter of 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000119312523065311/0001193125-23-065311-index.htm
- Earnings Releases
  Akebia Therapeutics, Inc. reported 2023 results: revenue $175-$180 million. Guidance initiated.
  - Period: 2023
  - Revenue: $175-$180 million
  - Guidance: initiated
  - Result: guidance update
  source text: Sets 2023 Auryxia net product revenue guidance at $175-$180M
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000119312523065311/0001193125-23-065311-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.